- Home
- GLTO vs ADIL Comparison
GLTO vs ADIL Comparison
Compare GLTO & ADIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLTO
- ADIL
- Stock Information
- Founded
- GLTO 2011
- ADIL 2010
- Country
- GLTO Denmark
- ADIL United States
- Employees
- GLTO N/A
- ADIL N/A
- Industry
- GLTO Biotechnology: Pharmaceutical Preparations
- ADIL Biotechnology: Pharmaceutical Preparations
- Sector
- GLTO Health Care
- ADIL Health Care
- Exchange
- GLTO Nasdaq
- ADIL Nasdaq
- Market Cap
- GLTO 7.5M
- ADIL 6.5M
- IPO Year
- GLTO 2020
- ADIL 2018
- Fundamental
- Price
- GLTO $4.70
- ADIL $1.07
- Analyst Decision
- GLTO Buy
- ADIL Strong Buy
- Analyst Count
- GLTO 1
- ADIL 1
- Target Price
- GLTO $10.00
- ADIL $8.00
- AVG Volume (30 Days)
- GLTO 20.6K
- ADIL 212.3K
- Earning Date
- GLTO 11-01-2024
- ADIL 11-13-2024
- Dividend Yield
- GLTO N/A
- ADIL N/A
- EPS Growth
- GLTO N/A
- ADIL N/A
- EPS
- GLTO N/A
- ADIL N/A
- Revenue
- GLTO N/A
- ADIL N/A
- Revenue This Year
- GLTO N/A
- ADIL N/A
- Revenue Next Year
- GLTO N/A
- ADIL N/A
- P/E Ratio
- GLTO N/A
- ADIL N/A
- Revenue Growth
- GLTO N/A
- ADIL N/A
- 52 Week Low
- GLTO $4.40
- ADIL $0.77
- 52 Week High
- GLTO $23.50
- ADIL $4.17
- Technical
- Relative Strength Index (RSI)
- GLTO 26.70
- ADIL 48.27
- Support Level
- GLTO $4.40
- ADIL $1.05
- Resistance Level
- GLTO $5.42
- ADIL $1.16
- Average True Range (ATR)
- GLTO 0.37
- ADIL 0.09
- MACD
- GLTO -0.01
- ADIL -0.01
- Stochastic Oscillator
- GLTO 16.81
- ADIL 23.33
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.
About ADIL Adial Pharmaceuticals Inc
Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company develops prescription medications for addiction and related disorders. Its lead product is AD04, which is for the treatment of alcohol use disorder. The active ingredient in AD04 is ondansetron, a serotonin-3 antagonist.